SOMERSET, N.J. -- (BUSINESS WIRE) -- Catalent, Inc. (NYSE:CTLT), the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic, and consumer health products, today announced that it has appointed Jack Stahl and Rolf Classon to its Board of Directors.
Mr. Jack Stahl was President and Chief Executive Officer of Revlon, Inc. between 2002 and 2006. Previously, he acted as President and Chief Operating Officer of The Coca-Cola Company from 2000 to 2001. Mr. Stahl also serves on the Boards of Coty, Inc., Delhaize Group, and the U.S. Board of Advisors of CVC Capital. Additionally, Mr. Stahl formerly served on the Boards of Schering-Plough Corporation and Dr Pepper Snapple Group. He holds a Bachelor’s degree in Economics from Emory University and a Master’s degree from the Wharton School of Business at the University of Pennsylvania.
Mr. Rolf Classon was Chairman of the Executive Committee at Bayer HealthCare AG, a subsidiary of Bayer AG, from October 2002 until his retirement in July 2004. He served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President from 1991 to 1995. Prior to 1991, Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon currently serves as Chairman of the Boards of Auxilium Pharmaceuticals, Inc., Hill-Rom Corporation, and Tecan Group Ltd., and he serves on the Board of Fresenius Medical Care. Mr. Classon served as Vice Chairman of Auxilium Pharmaceuticals, Inc. from March 2005 to April 2005, and he was interim Chief Executive Officer of Hill-Rom Corporation from May 2005 until March 2006. Mr. Classon also served as a Director on the Boards of Millipore Corporation, Prometheus Laboratories Inc., and Enzon Pharmaceuticals, Inc. Mr. Classon received his Chemical Engineering Certificate from the Gothenburg School of Engineering and a Business degree from the Gothenburg University.
Messrs. Stahl and Classon have also joined Catalent’s Audit Committee, with Mr. Stahl serving as Chair.
“We welcome both Jack and Rolf to our Board,” commented John Chiminski, President and CEO, Catalent, Inc. “Both are senior healthcare executives, with a wealth of knowledge and experience within the sector. We will look to draw upon their expertise as we embark on the next, exciting stage of our Company’s history.”
About Catalent, Inc.
Catalent, Inc. is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com
Forward Looking Statements
This press release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”, “likely”, “may”, “will”, “would” or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent, Inc.’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in our Prospectus dated July 30, 2014 filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent, Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments unless required by law.
More products. Better treatments. Reliably supplied.™